

**Supplementary Table 3. Comparison between SLE patients with and without COVID-19 (SARS-CoV-2 positive)**

Variable	Patients with COVID-19 (n = 20)	Negative controls (n = 263)	p value
Age ≥ 50 years <sup>a</sup>	15 (75.0)	180 (68.4)	0.541
Female sex <sup>a</sup>	16 (80.0)	219 (83.3)	0.707
Comorbidities <sup>b</sup>			
Diabetes mellitus	0	3 (1.1)	0.631
Hypertension	0	5 (1.9)	0.534
Cardiovascular disease	0	6 (2.3)	0.495
Chronic lung disease	1 (5.0)	2 (0.8)	0.074
Chronic kidney disease	0	2 (0.8)	0.696
Current medications <sup>c</sup>			
Glucocorticoid	13 (65.0)	156 (59.3)	0.617
Glucocorticoid dose ≥ 10 mg/day	13 (65.0)	144 (54.8)	0.374
Hydroxychloroquine	3 (15.0)	65 (24.7)	0.327
Methotrexate	1 (5.0)	10 (3.8)	0.789
Tacrolimus	0	6 (2.3)	0.495

Values are presented as number (%).

SLE, systemic lupus erythematosus; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup>As recorded on the date of COVID-19 testing.

<sup>b</sup>Information on comorbidities is based on diagnostic codes (International Classification of Diseases, 10th edition [ICD-10]) in the claims data from January 1, 2015, to the test date.

<sup>c</sup>Use of medications within 3 months of the examination date was obtained from the database.